ENTITY
Yichang HEC Changjiang Pharma

Yichang HEC Changjiang Pharma (1558 HK)

61
Analysis
Health CareHong Kong
YiChang HEC ChangJiang Pharmaceutical Co Ltd develops a variety of drugs. The Company develops and sells drugs for anti-virus, metabolic diseases, cardiovascular, and more.
more
Refresh
19 May 2024 07:05

Yichang HEC (1558 HK): Absorption Via Speculative Scrip. Avoid

Maybe this gets up. Maybe this is worth HK$19.30/share.  Too many maybes. If in, I'd vote this transaction down. If not in, I'd be looking elsewhere.

Logo
420 Views
Share
16 May 2024 08:55

HEC CJ Pharma (1558.HK)'s Merger Deal with Sunshine Lake Pharma - Almost No Investment Value

​Sunshine Lake Pharma plans to privatize and merge with CJ Pharma.However, with an outdated pipeline, the new entity's valuation performance will...

Logo
249 Views
Share
11 May 2024 23:48

HEC CJ Pharma (1558 HK): Pre-Conditional Share Exchange Offer from Largest Shareholder

There is scrip valuation uncertainty as the offeror is unlisted, and its valuation hinges on pipeline products. Nevertheless, the deal should get...

Logo
445 Views
Share
04 Jan 2024 09:30

HEC Pharma (1558 HK): Strong Performance to Continue as Flu Activity Is On Rise In China

HEC Pharma should benefit from the upsurge in respiratory illness in China. With a forward P/E of 4.8x and 14% YoY EPS growth expectation for 2024,...

Logo
630 Views
Share
02 Oct 2023 21:57

HEC Pharma (1558 HK): Robust 1H23 Performance on Flu Outbreak in China

HEC Pharma reports impressive revenue growth of 148% YoY in 1H23, driven by strong sales of Kewei for influenza treatment. The company obtained...

Logo
432 Views
Share
x